Skip to content

Prevention of Cisplatin-induced Nephrotoxicity

Nephroprotective Effects of Aminophylline in Pediatric Oncologic Patient on Cisplatin Based Chemotherapy; Double Blind Randomized Controlled Trial

Status
Not yet recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06196853
Enrollment
24
Registered
2024-01-09
Start date
2025-12-01
Completion date
2026-09-30
Last updated
2025-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury, Renal Tubulopathy

Keywords

Acute Kidney Injury, Chemotherapy induced kidney related complication

Brief summary

The research design is a prospective, randomized, controlled clinical trial in children to study effect of aminophylline in preserving renal function in oncologic patient received cisplatin either combined with other CMT or used alone. The participants in both groups will receive standard protocol pre-cisplatin infusion which include hydration with 5%DNSS/2 with KCL and MgSO4 IV infusion. In the treatment group, the participants will receive aminophylline infusion in the first 24 hours along with cisplatin, followed by oral aminophylline oral three times daily orally for 4 consecutive days post cisplatin. The aminophylline serum level will be maintained at the therapeutic range 10-20 mg. The side effect of aminophylline including nausea, vomiting and ECG will be monitored. The collected data including urine volume, GFR (estimated by cystatin C-creatinine based equation and by radiopharmaceutical-Tc DTPA), and renal tubular biomarker (urine B2 macroglobulin and urine NGAL) will be collected at baseline before receiving cisplatin, 24 hours and 5 days post cisplatin.

Interventions

DRUGAminophylline

Give aminophylline for 5 days to keep serum theophylline level 5-15 mg/dl

Sponsors

Mahidol University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
No minimum to 18 Years
Healthy volunteers
No

Inclusion criteria

* Age under 18 years old * Oncology patients who receive cisplatin-based therapy

Exclusion criteria

* Preexisting renal anomalies * Preexisting GFR less than 60 ml/min/1.73 m2 * Contraindication of aminophylline including structural heart disease, arrhythmia, hyperthyroidism, chronic liver disease, epilepsy * Aminophylline use within 24 hours prior to study entry

Design outcomes

Primary

MeasureTime frameDescription
Change from baseline in glomerular filtration rateBaseline before cisplatin, and 48 hours 72 hours and 21 days post cisplatinGlomerular filtration rate is calculated using Cystatin C-creatinine-based equations. (ref. Kidney Int. 2012 Aug;82(4):445-53.)

Secondary

MeasureTime frameDescription
Renal tubular biomarkersBaseline before cisplatin, and 48 hours 72 hours and 21 days post cisplatinUrine for beta2 macroglobulin

Countries

Thailand

Contacts

Primary ContactAnirut Pattaragarn, MD
apattaragarn@yahoo.com66816651020

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026